These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 34749770)

  • 1. Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial.
    Guttmann-Gruber C; Piñón Hofbauer J; Tockner B; Reichl V; Klausegger A; Hofbauer P; Wolkersdorfer M; Tham KC; Lim SS; Common JE; Diem A; Ude-Schoder K; Hitzl W; Lagler F; Reichelt J; Bauer JW; Lang R; Laimer M
    Orphanet J Rare Dis; 2021 Nov; 16(1):473. PubMed ID: 34749770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
    Guide SV; Gonzalez ME; Bağcı IS; Agostini B; Chen H; Feeney G; Steimer M; Kapadia B; Sridhar K; Quesada Sanchez L; Gonzalez F; Van Ligten M; Parry TJ; Chitra S; Kammerman LA; Krishnan S; Marinkovich MP
    N Engl J Med; 2022 Dec; 387(24):2211-2219. PubMed ID: 36516090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.
    Woodley DT; Cogan J; Hou Y; Lyu C; Marinkovich MP; Keene D; Chen M
    J Clin Invest; 2017 Aug; 127(8):3028-3038. PubMed ID: 28691931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.
    So JY; Nazaroff J; Iwummadu CV; Harris N; Gorell ES; Fulchand S; Bailey I; McCarthy D; Siprashvili Z; Marinkovich MP; Tang JY; Chiou AS
    Orphanet J Rare Dis; 2022 Oct; 17(1):377. PubMed ID: 36253825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of oral JAK1 or JAK1/2 inhibitor for treating refractory pruritus in dystrophic epidermolysis bullosa: A retrospective case series.
    Kwon IJ; Kim SE; Kim SC; Lee SE
    J Dermatol; 2024 Mar; 51(3):441-447. PubMed ID: 38115742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCB5
    Dieter K; Niebergall-Roth E; Daniele C; Fluhr S; Frank NY; Ganss C; Kiritsi D; McGrath JA; Tolar J; Frank MH; Kluth MA
    Cytotherapy; 2023 Jul; 25(7):782-788. PubMed ID: 36868990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.
    Eichstadt S; Barriga M; Ponakala A; Teng C; Nguyen NT; Siprashvili Z; Nazaroff J; Gorell ES; Chiou AS; Taylor L; Khuu P; Keene DR; Rieger K; Khosla RK; Furukawa LK; Lorenz HP; Marinkovich MP; Tang JY
    JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31578311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose calcipotriol can elicit wound closure, anti-microbial, and anti-neoplastic effects in epidermolysis bullosa keratinocytes.
    Guttmann-Gruber C; Tockner B; Scharler C; Hüttner C; Common JE; Tay ASL; Denil SLIJ; Klausegger A; Trost A; Breitenbach J; Schnitzhofer P; Hofbauer P; Wolkersdorfer M; Diem A; Laimer M; Strunk D; Bauer JW; Reichelt J; Lang R; Piñón Hofbauer J
    Sci Rep; 2018 Sep; 8(1):13430. PubMed ID: 30194425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ T helper 2 cells which may contribute to pruritus in lesional skin.
    Aala WJF; Hou PC; Hong YK; Lin YC; Lee YR; Tu WT; Papanikolaou M; Benzian-Olsson N; Onoufriadis A; I Chen Harn H; Hwang DY; Cheng SM; Lu K; Chen PC; McGrath JA; Hsu CK
    Br J Dermatol; 2024 Jul; 191(2):252-260. PubMed ID: 38477474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
    Siprashvili Z; Nguyen NT; Gorell ES; Loutit K; Khuu P; Furukawa LK; Lorenz HP; Leung TH; Keene DR; Rieger KE; Khavari P; Lane AT; Tang JY; Marinkovich MP
    JAMA; 2016 Nov; 316(17):1808-1817. PubMed ID: 27802546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization. Results of a randomized, double-blind, vehicle-controlled, right/left comparative study.
    Kragballe K; Steijlen PM; Ibsen HH; van de Kerkhof PC; Esmann J; Sorensen LH; Axelsen MB
    Arch Dermatol; 1995 May; 131(5):556-60. PubMed ID: 7741542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.
    Venugopal SS; Yan W; Frew JW; Cohn HI; Rhodes LM; Tran K; Melbourne W; Nelson JA; Sturm M; Fogarty J; Marinkovich MP; Igawa S; Ishida-Yamamoto A; Murrell DF
    J Am Acad Dermatol; 2013 Dec; 69(6):898-908.e7. PubMed ID: 24075228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics associated with increased wound size in patients with recessive dystrophic epidermolysis bullosa.
    Solis DC; Gorell ES; Teng C; Barriga M; Nazaroff J; Li S; Subica A; Lu Y; Marinkovich MP; Tang JY
    Pediatr Dermatol; 2021 May; 38(3):704-706. PubMed ID: 33749033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa.
    Paller AS; Pope E; Rudin D; Malyala A; Ramsdell D; Johnson R; Landy H; Murrell DF;
    Orphanet J Rare Dis; 2022 Aug; 17(1):314. PubMed ID: 35964087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
    Bornert O; Hogervorst M; Nauroy P; Bischof J; Swildens J; Athanasiou I; Tufa SF; Keene DR; Kiritsi D; Hainzl S; Murauer EM; Marinkovich MP; Platenburg G; Hausser I; Wally V; Ritsema T; Koller U; Haisma EM; Nyström A
    J Invest Dermatol; 2021 Apr; 141(4):883-893.e6. PubMed ID: 32946877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study.
    Dubertret L; Wallach D; Souteyrand P; Perussel M; Kalis B; Meynadier J; Chevrant-Breton J; Beylot C; Bazex JA; Jurgensen HJ
    J Am Acad Dermatol; 1992 Dec; 27(6 Pt 1):983-8. PubMed ID: 1479106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dystrophic epidermolysis bullosa pruriginosa is not associated with frequent FLG gene mutations.
    Schumann H; Has C; Kohlhase J; Bruckner-Tuderman L
    Br J Dermatol; 2008 Aug; 159(2):464-9. PubMed ID: 18565177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial.
    Chiou AS; Choi S; Barriga M; Dutt-Singkh Y; Solis DC; Nazaroff J; Bailey-Healy I; Li S; Shu K; Joing M; Kwon P; Tang JY
    J Am Acad Dermatol; 2020 Jun; 82(6):1415-1421. PubMed ID: 31541747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic granulocyte colony-stimulating factor (G-CSF) enhances wound healing in dystrophic epidermolysis bullosa (DEB): Results of a pilot trial.
    Fine JD; Manes B; Frangoul H
    J Am Acad Dermatol; 2015 Jul; 73(1):56-61. PubMed ID: 25956659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of trimethoprim in wound healing of patients with epidermolysis bullosa: a feasibility trial.
    Lara-Corrales I; Parkin PC; Stephens D; Hamilton J; Koren G; Weinstein M; Sibbald RG; Pope E
    J Am Acad Dermatol; 2012 Feb; 66(2):264-70. PubMed ID: 22153787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.